#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The liver is the central organ of lipid metabolism .
2-1	16-19	The	object[2]	new[2]	coref	2-4[3_2]
2-2	20-25	liver	object[2]	new[2]	_	_
2-3	26-28	is	_	_	_	_
2-4	29-32	the	object[3]	giv[3]	coref	3-7[8_3]
2-5	33-40	central	object[3]	giv[3]	_	_
2-6	41-46	organ	object[3]	giv[3]	_	_
2-7	47-49	of	object[3]	giv[3]	_	_
2-8	50-55	lipid	object[3]|substance|abstract[5]	giv[3]|new|new[5]	coref|coref	11-7|18-7[122_5]
2-9	56-66	metabolism	object[3]|abstract[5]	giv[3]|new[5]	_	_
2-10	67-68	.	_	_	_	_

#Text=Dietary fatty acids are transported to the liver and oxidized to produce as much energy as the hepatocyte needs .
3-1	69-76	Dietary	substance[7]	new[7]	coref	4-1[12_7]
3-2	77-82	fatty	abstract|substance[7]	new|new[7]	coref	4-3
3-3	83-88	acids	substance[7]	new[7]	_	_
3-4	89-92	are	_	_	_	_
3-5	93-104	transported	_	_	_	_
3-6	105-107	to	_	_	_	_
3-7	108-111	the	object[8]	giv[8]	coref	5-14[0_8]
3-8	112-117	liver	object[8]	giv[8]	_	_
3-9	118-121	and	_	_	_	_
3-10	122-130	oxidized	_	_	_	_
3-11	131-133	to	_	_	_	_
3-12	134-141	produce	_	_	_	_
3-13	142-144	as	abstract[9]	new[9]	_	_
3-14	145-149	much	abstract[9]	new[9]	_	_
3-15	150-156	energy	abstract[9]	new[9]	_	_
3-16	157-159	as	_	_	_	_
3-17	160-163	the	animal[10]	new[10]	coref	4-15[15_10]
3-18	164-174	hepatocyte	animal[10]	new[10]	_	_
3-19	175-180	needs	_	_	_	_
3-20	181-182	.	_	_	_	_

#Text=The excess fatty acids are converted to triglycerides ( TG ) and stored in the hepatocyte .
4-1	183-186	The	substance[12]	giv[12]	_	_
4-2	187-193	excess	substance[12]	giv[12]	_	_
4-3	194-199	fatty	abstract|substance[12]	giv|giv[12]	coref	14-3
4-4	200-205	acids	substance[12]	giv[12]	_	_
4-5	206-209	are	_	_	_	_
4-6	210-219	converted	_	_	_	_
4-7	220-222	to	_	_	_	_
4-8	223-236	triglycerides	substance	new	appos	4-10
4-9	237-238	(	_	_	_	_
4-10	239-241	TG	substance	giv	coref	5-5
4-11	242-243	)	_	_	_	_
4-12	244-247	and	_	_	_	_
4-13	248-254	stored	_	_	_	_
4-14	255-257	in	_	_	_	_
4-15	258-261	the	animal[15]	giv[15]	_	_
4-16	262-272	hepatocyte	animal[15]	giv[15]	_	_
4-17	273-274	.	_	_	_	_

#Text=When the amount of TG accounts for more than 5 % of the liver weight , the organ function is impaired , and this condition is known as fatty liver disease .
5-1	275-279	When	_	_	_	_
5-2	280-283	the	substance[16]	new[16]	_	_
5-3	284-290	amount	substance[16]	new[16]	_	_
5-4	291-293	of	substance[16]	new[16]	_	_
5-5	294-296	TG	substance[16]|substance	new[16]|giv	_	_
5-6	297-305	accounts	_	_	_	_
5-7	306-309	for	_	_	_	_
5-8	310-314	more	abstract[18]	new[18]	_	_
5-9	315-319	than	abstract[18]	new[18]	_	_
5-10	320-321	5	abstract[18]	new[18]	_	_
5-11	322-323	%	abstract[18]	new[18]	_	_
5-12	324-326	of	abstract[18]	new[18]	_	_
5-13	327-330	the	abstract[18]|abstract[20]	new[18]|new[20]	_	_
5-14	331-336	liver	abstract[18]|object|abstract[20]	new[18]|giv|new[20]	coref	5-18
5-15	337-343	weight	abstract[18]|abstract[20]	new[18]|new[20]	_	_
5-16	344-345	,	_	_	_	_
5-17	346-349	the	abstract[22]	new[22]	_	_
5-18	350-355	organ	object|abstract[22]	giv|new[22]	coref	5-30
5-19	356-364	function	abstract[22]	new[22]	_	_
5-20	365-367	is	_	_	_	_
5-21	368-376	impaired	_	_	_	_
5-22	377-378	,	_	_	_	_
5-23	379-382	and	_	_	_	_
5-24	383-387	this	abstract[23]	new[23]	_	_
5-25	388-397	condition	abstract[23]	new[23]	_	_
5-26	398-400	is	_	_	_	_
5-27	401-406	known	_	_	_	_
5-28	407-409	as	_	_	_	_
5-29	410-415	fatty	abstract[25]	new[25]	coref	10-1[54_25]
5-30	416-421	liver	object|abstract[25]	giv|new[25]	coref	6-12[29_0]
5-31	422-429	disease	abstract[25]	new[25]	_	_
5-32	430-431	.	_	_	_	_

#Text=Chronic alcohol intake has long been considered the major cause of alcoholic fatty liver , while non-alcoholic fatty liver has been shown to be unrelated to alcohol intake .
6-1	432-439	Chronic	event[27]	new[27]	coref	6-27[32_27]
6-2	440-447	alcohol	substance|event[27]	new|new[27]	coref	6-27
6-3	448-454	intake	event[27]	new[27]	_	_
6-4	455-458	has	_	_	_	_
6-5	459-463	long	_	_	_	_
6-6	464-468	been	_	_	_	_
6-7	469-479	considered	_	_	_	_
6-8	480-483	the	abstract[28]	new[28]	_	_
6-9	484-489	major	abstract[28]	new[28]	_	_
6-10	490-495	cause	abstract[28]	new[28]	_	_
6-11	496-498	of	abstract[28]	new[28]	_	_
6-12	499-508	alcoholic	abstract[28]|object[29]	new[28]|giv[29]	coref	6-17[30_29]
6-13	509-514	fatty	abstract[28]|object[29]	new[28]|giv[29]	_	_
6-14	515-520	liver	abstract[28]|object[29]	new[28]|giv[29]	_	_
6-15	521-522	,	_	_	_	_
6-16	523-528	while	_	_	_	_
6-17	529-542	non-alcoholic	object[30]	giv[30]	coref	7-4[34_30]
6-18	543-548	fatty	object[30]	giv[30]	_	_
6-19	549-554	liver	object[30]	giv[30]	_	_
6-20	555-558	has	_	_	_	_
6-21	559-563	been	_	_	_	_
6-22	564-569	shown	_	_	_	_
6-23	570-572	to	_	_	_	_
6-24	573-575	be	_	_	_	_
6-25	576-585	unrelated	_	_	_	_
6-26	586-588	to	_	_	_	_
6-27	589-596	alcohol	substance|event[32]	giv|giv[32]	coref	7-13[37_32]
6-28	597-603	intake	event[32]	giv[32]	_	_
6-29	604-605	.	_	_	_	_

#Text=The causes of non-alcoholic fatty liver are lifestyle habits , which include excessive dietary intake and lack of energy consumption .
7-1	606-609	The	abstract[33]	new[33]	coref	7-8[36_33]
7-2	610-616	causes	abstract[33]	new[33]	_	_
7-3	617-619	of	abstract[33]	new[33]	_	_
7-4	620-633	non-alcoholic	abstract[33]|object[34]	new[33]|giv[34]	coref	9-17[52_34]
7-5	634-639	fatty	abstract[33]|object[34]	new[33]|giv[34]	_	_
7-6	640-645	liver	abstract[33]|object[34]	new[33]|giv[34]	_	_
7-7	646-649	are	_	_	_	_
7-8	650-659	lifestyle	abstract|abstract[36]	new|giv[36]	coref	8-8
7-9	660-666	habits	abstract[36]	giv[36]	_	_
7-10	667-668	,	abstract[36]	giv[36]	_	_
7-11	669-674	which	abstract[36]	giv[36]	_	_
7-12	675-682	include	abstract[36]	giv[36]	_	_
7-13	683-692	excessive	abstract[36]|event[37]	giv[36]|giv[37]	_	_
7-14	693-700	dietary	abstract[36]|event[37]	giv[36]|giv[37]	_	_
7-15	701-707	intake	abstract[36]|event[37]	giv[36]|giv[37]	_	_
7-16	708-711	and	abstract[36]	giv[36]	_	_
7-17	712-716	lack	abstract[36]|abstract[38]	giv[36]|new[38]	ana	8-3[0_38]
7-18	717-719	of	abstract[36]|abstract[38]	giv[36]|new[38]	_	_
7-19	720-726	energy	abstract[36]|abstract[38]|event[39]	giv[36]|new[38]|new[39]	_	_
7-20	727-738	consumption	abstract[36]|abstract[38]|event[39]	giv[36]|new[38]|new[39]	_	_
7-21	739-740	.	_	_	_	_

#Text=Therefore , it is often accompanied by lifestyle diseases such as obesity , diabetes , and metabolic syndrome .
8-1	741-750	Therefore	_	_	_	_
8-2	751-752	,	_	_	_	_
8-3	753-755	it	abstract	giv	_	_
8-4	756-758	is	_	_	_	_
8-5	759-764	often	_	_	_	_
8-6	765-776	accompanied	_	_	_	_
8-7	777-779	by	_	_	_	_
8-8	780-789	lifestyle	abstract|abstract[42]	giv|new[42]	coref	9-10[50_42]
8-9	790-798	diseases	abstract[42]	new[42]	_	_
8-10	799-803	such	abstract[42]	new[42]	_	_
8-11	804-806	as	abstract[42]	new[42]	_	_
8-12	807-814	obesity	abstract[42]|abstract|abstract[44]	new[42]|new|new[44]	coref|coref	13-6|13-6[67_44]
8-13	815-816	,	abstract[42]|abstract[44]	new[42]|new[44]	_	_
8-14	817-825	diabetes	abstract[42]|abstract[44]|abstract	new[42]|new[44]|new	coref	13-8
8-15	826-827	,	abstract[42]|abstract[44]	new[42]|new[44]	_	_
8-16	828-831	and	abstract[42]|abstract[44]	new[42]|new[44]	_	_
8-17	832-841	metabolic	abstract[42]|abstract[44]|person|abstract[47]	new[42]|new[44]|new|new[47]	_	_
8-18	842-850	syndrome	abstract[42]|abstract[44]|abstract[47]	new[42]|new[44]|new[47]	_	_
8-19	851-852	.	_	_	_	_

#Text=In recent times , with the growing incidence of these diseases , the attention paid to non-alcoholic fatty liver is gradually increasing .
9-1	853-855	In	_	_	_	_
9-2	856-862	recent	time[48]	new[48]	_	_
9-3	863-868	times	time[48]	new[48]	_	_
9-4	869-870	,	_	_	_	_
9-5	871-875	with	_	_	_	_
9-6	876-879	the	abstract[49]	new[49]	_	_
9-7	880-887	growing	abstract[49]	new[49]	_	_
9-8	888-897	incidence	abstract[49]	new[49]	_	_
9-9	898-900	of	abstract[49]	new[49]	_	_
9-10	901-906	these	abstract[49]|abstract[50]	new[49]|giv[50]	coref	25-23[181_50]
9-11	907-915	diseases	abstract[49]|abstract[50]	new[49]|giv[50]	_	_
9-12	916-917	,	_	_	_	_
9-13	918-921	the	abstract[51]	new[51]	_	_
9-14	922-931	attention	abstract[51]	new[51]	_	_
9-15	932-936	paid	abstract[51]	new[51]	_	_
9-16	937-939	to	abstract[51]	new[51]	_	_
9-17	940-953	non-alcoholic	abstract[51]|object[52]	new[51]|giv[52]	coref	10-3[0_52]
9-18	954-959	fatty	abstract[51]|object[52]	new[51]|giv[52]	_	_
9-19	960-965	liver	abstract[51]|object[52]	new[51]|giv[52]	_	_
9-20	966-968	is	_	_	_	_
9-21	969-978	gradually	_	_	_	_
9-22	979-989	increasing	_	_	_	_
9-23	990-991	.	_	_	_	_

#Text=Non-alcoholic fatty liver disease ( NAFLD ) shows various stages .
10-1	992-1005	Non-alcoholic	abstract[54]	giv[54]	appos	10-6[0_54]
10-2	1006-1011	fatty	abstract[54]	giv[54]	_	_
10-3	1012-1017	liver	object|abstract[54]	giv|giv[54]	coref	14-11[79_0]
10-4	1018-1025	disease	abstract[54]	giv[54]	_	_
10-5	1026-1027	(	_	_	_	_
10-6	1028-1033	NAFLD	abstract	giv	coref	13-18
10-7	1034-1035	)	_	_	_	_
10-8	1036-1041	shows	_	_	_	_
10-9	1042-1049	various	abstract[56]	new[56]	_	_
10-10	1050-1056	stages	abstract[56]	new[56]	_	_
10-11	1057-1058	.	_	_	_	_

#Text=Simple hepatic steatosis is characterized by lipid accumulation in hepatocytes .
11-1	1059-1065	Simple	abstract[57]	new[57]	_	_
11-2	1066-1073	hepatic	abstract[57]	new[57]	_	_
11-3	1074-1083	steatosis	abstract[57]	new[57]	_	_
11-4	1084-1086	is	_	_	_	_
11-5	1087-1100	characterized	_	_	_	_
11-6	1101-1103	by	_	_	_	_
11-7	1104-1109	lipid	substance|abstract[59]	giv|new[59]	coref|coref	18-7|18-13[123_59]
11-8	1110-1122	accumulation	abstract[59]	new[59]	_	_
11-9	1123-1125	in	abstract[59]	new[59]	_	_
11-10	1126-1137	hepatocytes	abstract[59]|animal	new[59]|new	coref	18-16
11-11	1138-1139	.	_	_	_	_

#Text=Non-alcoholic steatohepatitis ( NASH ) can be further developed into cirrhosis and hepatocellular carcinoma .
12-1	1140-1153	Non-alcoholic	abstract[61]	new[61]	appos	12-4[0_61]
12-2	1154-1169	steatohepatitis	abstract[61]	new[61]	_	_
12-3	1170-1171	(	_	_	_	_
12-4	1172-1176	NASH	abstract	giv	_	_
12-5	1177-1178	)	_	_	_	_
12-6	1179-1182	can	_	_	_	_
12-7	1183-1185	be	_	_	_	_
12-8	1186-1193	further	_	_	_	_
12-9	1194-1203	developed	_	_	_	_
12-10	1204-1208	into	_	_	_	_
12-11	1209-1218	cirrhosis	abstract	new	_	_
12-12	1219-1222	and	_	_	_	_
12-13	1223-1237	hepatocellular	substance[64]	new[64]	_	_
12-14	1238-1247	carcinoma	substance[64]	new[64]	_	_
12-15	1248-1249	.	_	_	_	_

#Text=Although many factors such as obesity , diabetes , and inflammation have been implicated in relation to NAFLD in humans , the underlying mechanism of the development and progression of NAFLD remains unclear .
13-1	1250-1258	Although	_	_	_	_
13-2	1259-1263	many	abstract[65]	new[65]	coref	14-14[82_65]
13-3	1264-1271	factors	abstract[65]	new[65]	_	_
13-4	1272-1276	such	abstract[65]	new[65]	_	_
13-5	1277-1279	as	abstract[65]	new[65]	_	_
13-6	1280-1287	obesity	abstract[65]|abstract|abstract[67]	new[65]|giv|giv[67]	_	_
13-7	1288-1289	,	abstract[65]|abstract[67]	new[65]|giv[67]	_	_
13-8	1290-1298	diabetes	abstract[65]|abstract[67]|abstract	new[65]|giv[67]|giv	_	_
13-9	1299-1300	,	abstract[65]|abstract[67]	new[65]|giv[67]	_	_
13-10	1301-1304	and	abstract[65]|abstract[67]	new[65]|giv[67]	_	_
13-11	1305-1317	inflammation	abstract[65]|abstract[67]|abstract	new[65]|giv[67]|new	_	_
13-12	1318-1322	have	_	_	_	_
13-13	1323-1327	been	_	_	_	_
13-14	1328-1338	implicated	_	_	_	_
13-15	1339-1341	in	_	_	_	_
13-16	1342-1350	relation	_	_	_	_
13-17	1351-1353	to	_	_	_	_
13-18	1354-1359	NAFLD	abstract	giv	coref	13-31
13-19	1360-1362	in	_	_	_	_
13-20	1363-1369	humans	animal	new	_	_
13-21	1370-1371	,	_	_	_	_
13-22	1372-1375	the	abstract[72]	new[72]	_	_
13-23	1376-1386	underlying	abstract[72]	new[72]	_	_
13-24	1387-1396	mechanism	abstract[72]	new[72]	_	_
13-25	1397-1399	of	abstract[72]	new[72]	_	_
13-26	1400-1403	the	abstract[72]|event[73]	new[72]|new[73]	_	_
13-27	1404-1415	development	abstract[72]|event[73]	new[72]|new[73]	_	_
13-28	1416-1419	and	abstract[72]	new[72]	_	_
13-29	1420-1431	progression	abstract[72]|event[74]	new[72]|new[74]	_	_
13-30	1432-1434	of	abstract[72]|event[74]	new[72]|new[74]	_	_
13-31	1435-1440	NAFLD	abstract[72]|event[74]|abstract	new[72]|new[74]|giv	coref	15-27
13-32	1441-1448	remains	_	_	_	_
13-33	1449-1456	unclear	_	_	_	_
13-34	1457-1458	.	_	_	_	_

#Text=When free fatty acid ( FFA ) is overloaded in the body , FFA uptake factors such as cluster of differentiation 36 ( CD36 ) and fatty acid transport proteins ( FATPs ) are significantly up-regulated , and then excessive FFA is accepted into the liver , gradually accumulating .
14-1	1459-1463	When	_	_	_	_
14-2	1464-1468	free	substance[77]	new[77]	coref	14-27[86_77]
14-3	1469-1474	fatty	abstract|substance[77]	giv|new[77]	_	_
14-4	1475-1479	acid	substance[77]	new[77]	_	_
14-5	1480-1481	(	_	_	_	_
14-6	1482-1485	FFA	abstract	new	coref	14-14
14-7	1486-1487	)	_	_	_	_
14-8	1488-1490	is	_	_	_	_
14-9	1491-1501	overloaded	_	_	_	_
14-10	1502-1504	in	_	_	_	_
14-11	1505-1508	the	object[79]	giv[79]	coref	14-45[91_79]
14-12	1509-1513	body	object[79]	giv[79]	_	_
14-13	1514-1515	,	_	_	_	_
14-14	1516-1519	FFA	abstract|abstract[82]	giv|giv[82]	coref|coref	14-40[90_0]|20-18[134_82]
14-15	1520-1526	uptake	abstract|abstract[82]	new|giv[82]	_	_
14-16	1527-1534	factors	abstract[82]	giv[82]	_	_
14-17	1535-1539	such	abstract[82]	giv[82]	_	_
14-18	1540-1542	as	abstract[82]	giv[82]	_	_
14-19	1543-1550	cluster	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
14-20	1551-1553	of	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
14-21	1554-1569	differentiation	abstract[82]|abstract[83]|abstract	giv[82]|new[83]|new	_	_
14-22	1570-1572	36	abstract[82]|abstract[83]	giv[82]|new[83]	_	_
14-23	1573-1574	(	abstract[82]	giv[82]	_	_
14-24	1575-1579	CD36	abstract[82]|abstract	giv[82]|giv	coref	15-16
14-25	1580-1581	)	abstract[82]	giv[82]	_	_
14-26	1582-1585	and	abstract[82]	giv[82]	_	_
14-27	1586-1591	fatty	abstract[82]|substance[86]|substance[88]	giv[82]|giv[86]|new[88]	coref	15-6[94_86]
14-28	1592-1596	acid	abstract[82]|substance[86]|substance[88]	giv[82]|giv[86]|new[88]	_	_
14-29	1597-1606	transport	abstract[82]|abstract|substance[88]	giv[82]|new|new[88]	_	_
14-30	1607-1615	proteins	abstract[82]|substance[88]	giv[82]|new[88]	_	_
14-31	1616-1617	(	_	_	_	_
14-32	1618-1623	FATPs	abstract	new	_	_
14-33	1624-1625	)	_	_	_	_
14-34	1626-1629	are	_	_	_	_
14-35	1630-1643	significantly	_	_	_	_
14-36	1644-1656	up-regulated	_	_	_	_
14-37	1657-1658	,	_	_	_	_
14-38	1659-1662	and	_	_	_	_
14-39	1663-1667	then	_	_	_	_
14-40	1668-1677	excessive	abstract[90]	giv[90]	_	_
14-41	1678-1681	FFA	abstract[90]	giv[90]	_	_
14-42	1682-1684	is	_	_	_	_
14-43	1685-1693	accepted	_	_	_	_
14-44	1694-1698	into	_	_	_	_
14-45	1699-1702	the	object[91]	giv[91]	coref	17-17[117_91]
14-46	1703-1708	liver	object[91]	giv[91]	_	_
14-47	1709-1710	,	_	_	_	_
14-48	1711-1720	gradually	_	_	_	_
14-49	1721-1733	accumulating	_	_	_	_
14-50	1734-1735	.	_	_	_	_

#Text=According to previous studies , palmitic acid and high-fat ( HF ) diet markedly increased CD36 expression , which is closely associated with the development of NAFLD .
15-1	1736-1745	According	_	_	_	_
15-2	1746-1748	to	_	_	_	_
15-3	1749-1757	previous	abstract[92]	new[92]	coref	16-3[101_92]
15-4	1758-1765	studies	abstract[92]	new[92]	_	_
15-5	1766-1767	,	_	_	_	_
15-6	1768-1776	palmitic	person|substance[94]|event[96]	new|giv[94]|new[96]	coref|coref	16-8[102_94]|21-6[147_96]
15-7	1777-1781	acid	substance[94]|event[96]	giv[94]|new[96]	_	_
15-8	1782-1785	and	event[96]	new[96]	_	_
15-9	1786-1794	high-fat	substance[95]|event[96]	new[95]|new[96]	coref	21-7[0_95]
15-10	1795-1796	(	substance[95]|event[96]	new[95]|new[96]	_	_
15-11	1797-1799	HF	substance[95]|event[96]	new[95]|new[96]	_	_
15-12	1800-1801	)	substance[95]|event[96]	new[95]|new[96]	_	_
15-13	1802-1806	diet	event[96]	new[96]	_	_
15-14	1807-1815	markedly	_	_	_	_
15-15	1816-1825	increased	_	_	_	_
15-16	1826-1830	CD36	abstract|abstract[98]	giv|new[98]	coref|coref	16-12[104_0]|20-15[132_98]
15-17	1831-1841	expression	abstract[98]	new[98]	_	_
15-18	1842-1843	,	abstract[98]	new[98]	_	_
15-19	1844-1849	which	abstract[98]	new[98]	_	_
15-20	1850-1852	is	abstract[98]	new[98]	_	_
15-21	1853-1860	closely	abstract[98]	new[98]	_	_
15-22	1861-1871	associated	abstract[98]	new[98]	_	_
15-23	1872-1876	with	abstract[98]	new[98]	_	_
15-24	1877-1880	the	abstract[98]|event[99]	new[98]|new[99]	_	_
15-25	1881-1892	development	abstract[98]|event[99]	new[98]|new[99]	_	_
15-26	1893-1895	of	abstract[98]|event[99]	new[98]|new[99]	_	_
15-27	1896-1901	NAFLD	abstract[98]|event[99]|abstract	new[98]|new[99]|giv	coref	19-8
15-28	1902-1903	.	_	_	_	_

#Text=Furthermore , several studies have indicated that fatty acid overflow by activated CD36 subsequently produced a higher level of reactive oxygen species ( ROS ) , which could be linked to oxidative stress .
16-1	1904-1915	Furthermore	_	_	_	_
16-2	1916-1917	,	_	_	_	_
16-3	1918-1925	several	abstract[101]	giv[101]	_	_
16-4	1926-1933	studies	abstract[101]	giv[101]	_	_
16-5	1934-1938	have	_	_	_	_
16-6	1939-1948	indicated	_	_	_	_
16-7	1949-1953	that	_	_	_	_
16-8	1954-1959	fatty	substance[102]|event[103]	giv[102]|new[103]	coref	20-29[138_102]
16-9	1960-1964	acid	substance[102]|event[103]	giv[102]|new[103]	_	_
16-10	1965-1973	overflow	event[103]	new[103]	_	_
16-11	1974-1976	by	event[103]	new[103]	_	_
16-12	1977-1986	activated	event[103]|abstract[104]	new[103]|giv[104]	_	_
16-13	1987-1991	CD36	event[103]|abstract[104]	new[103]|giv[104]	_	_
16-14	1992-2004	subsequently	_	_	_	_
16-15	2005-2013	produced	_	_	_	_
16-16	2014-2015	a	abstract[105]	new[105]	_	_
16-17	2016-2022	higher	abstract[105]	new[105]	_	_
16-18	2023-2028	level	abstract[105]	new[105]	_	_
16-19	2029-2031	of	abstract[105]	new[105]	_	_
16-20	2032-2040	reactive	abstract[105]|substance[106]|substance[107]	new[105]|new[106]|new[107]	appos	16-24[0_107]
16-21	2041-2047	oxygen	abstract[105]|substance[106]|substance[107]	new[105]|new[106]|new[107]	_	_
16-22	2048-2055	species	abstract[105]|substance[107]	new[105]|new[107]	_	_
16-23	2056-2057	(	_	_	_	_
16-24	2058-2061	ROS	substance	giv	coref	17-10
16-25	2062-2063	)	_	_	_	_
16-26	2064-2065	,	_	_	_	_
16-27	2066-2071	which	_	_	_	_
16-28	2072-2077	could	_	_	_	_
16-29	2078-2080	be	_	_	_	_
16-30	2081-2087	linked	_	_	_	_
16-31	2088-2090	to	_	_	_	_
16-32	2091-2100	oxidative	abstract[109]	new[109]	coref	17-1[111_109]
16-33	2101-2107	stress	abstract[109]	new[109]	_	_
16-34	2108-2109	.	_	_	_	_

#Text=Oxidative stress is the imbalance between the production of ROS and the activation of antioxidants in the body and results in several metabolic disorders .
17-1	2110-2119	Oxidative	abstract|abstract[111]	new|giv[111]	coref	17-4[112_111]
17-2	2120-2126	stress	abstract[111]	giv[111]	_	_
17-3	2127-2129	is	_	_	_	_
17-4	2130-2133	the	abstract[112]	giv[112]	coref	19-10[127_112]
17-5	2134-2143	imbalance	abstract[112]	giv[112]	_	_
17-6	2144-2151	between	abstract[112]	giv[112]	_	_
17-7	2152-2155	the	abstract[112]|abstract[113]	giv[112]|new[113]	coref	21-31[157_113]
17-8	2156-2166	production	abstract[112]|abstract[113]	giv[112]|new[113]	_	_
17-9	2167-2169	of	abstract[112]|abstract[113]	giv[112]|new[113]	_	_
17-10	2170-2173	ROS	abstract[112]|abstract[113]|substance	giv[112]|new[113]|giv	coref	21-34
17-11	2174-2177	and	abstract[112]	giv[112]	_	_
17-12	2178-2181	the	abstract[112]|event[115]	giv[112]|new[115]	_	_
17-13	2182-2192	activation	abstract[112]|event[115]	giv[112]|new[115]	_	_
17-14	2193-2195	of	abstract[112]|event[115]	giv[112]|new[115]	_	_
17-15	2196-2208	antioxidants	abstract[112]|event[115]|substance	giv[112]|new[115]|new	coref	25-5[177_0]
17-16	2209-2211	in	abstract[112]|event[115]	giv[112]|new[115]	_	_
17-17	2212-2215	the	abstract[112]|event[115]|object[117]	giv[112]|new[115]|giv[117]	ana	18-1[0_117]
17-18	2216-2220	body	abstract[112]|event[115]|object[117]	giv[112]|new[115]|giv[117]	_	_
17-19	2221-2224	and	_	_	_	_
17-20	2225-2232	results	_	_	_	_
17-21	2233-2235	in	_	_	_	_
17-22	2236-2243	several	abstract[118]	new[118]	coref	22-3[159_118]
17-23	2244-2253	metabolic	abstract[118]	new[118]	_	_
17-24	2254-2263	disorders	abstract[118]	new[118]	_	_
17-25	2264-2265	.	_	_	_	_

#Text=It particularly produces a disturbance in lipid metabolism , eventually leading to lipid accumulation in hepatocytes .
18-1	2266-2268	It	object	giv	coref	22-23[165_0]
18-2	2269-2281	particularly	_	_	_	_
18-3	2282-2290	produces	_	_	_	_
18-4	2291-2292	a	event[120]	new[120]	_	_
18-5	2293-2304	disturbance	event[120]	new[120]	_	_
18-6	2305-2307	in	event[120]	new[120]	_	_
18-7	2308-2313	lipid	event[120]|substance|abstract[122]	new[120]|giv|giv[122]	coref	27-8
18-8	2314-2324	metabolism	event[120]|abstract[122]	new[120]|giv[122]	_	_
18-9	2325-2326	,	_	_	_	_
18-10	2327-2337	eventually	_	_	_	_
18-11	2338-2345	leading	_	_	_	_
18-12	2346-2348	to	_	_	_	_
18-13	2349-2354	lipid	abstract[123]	giv[123]	coref	27-8[199_123]
18-14	2355-2367	accumulation	abstract[123]	giv[123]	_	_
18-15	2368-2370	in	abstract[123]	giv[123]	_	_
18-16	2371-2382	hepatocytes	abstract[123]|animal	giv[123]|giv	coref	20-12
18-17	2383-2384	.	_	_	_	_

#Text=Of the several existing pathogenic mechanisms of NAFLD , oxidative stress is considered a major contributor .
19-1	2385-2387	Of	_	_	_	_
19-2	2388-2391	the	abstract[125]	new[125]	_	_
19-3	2392-2399	several	abstract[125]	new[125]	_	_
19-4	2400-2408	existing	abstract[125]	new[125]	_	_
19-5	2409-2419	pathogenic	abstract[125]	new[125]	_	_
19-6	2420-2430	mechanisms	abstract[125]	new[125]	_	_
19-7	2431-2433	of	abstract[125]	new[125]	_	_
19-8	2434-2439	NAFLD	abstract[125]|abstract	new[125]|giv	_	_
19-9	2440-2441	,	_	_	_	_
19-10	2442-2451	oxidative	abstract[127]	giv[127]	coref	20-7[130_127]
19-11	2452-2458	stress	abstract[127]	giv[127]	_	_
19-12	2459-2461	is	_	_	_	_
19-13	2462-2472	considered	_	_	_	_
19-14	2473-2474	a	abstract[128]	new[128]	_	_
19-15	2475-2480	major	abstract[128]	new[128]	_	_
19-16	2481-2492	contributor	abstract[128]	new[128]	_	_
19-17	2493-2494	.	_	_	_	_

#Text=According to a previous study , uric acid-induced oxidative stress in hepatocytes significantly elevated the expression of lipogenesis factors such as acetyl-coenzyme A carboxylase ( ACC ) , fatty acid synthase ( FAS ) , and sterol regulatory element-binding protein-1c ( SREBP-1c ) .
20-1	2495-2504	According	_	_	_	_
20-2	2505-2507	to	_	_	_	_
20-3	2508-2509	a	abstract[129]	new[129]	coref	21-1[145_129]
20-4	2510-2518	previous	abstract[129]	new[129]	_	_
20-5	2519-2524	study	abstract[129]	new[129]	_	_
20-6	2525-2526	,	_	_	_	_
20-7	2527-2531	uric	abstract[130]	giv[130]	coref	22-7[160_130]
20-8	2532-2544	acid-induced	abstract[130]	giv[130]	_	_
20-9	2545-2554	oxidative	abstract[130]	giv[130]	_	_
20-10	2555-2561	stress	abstract[130]	giv[130]	_	_
20-11	2562-2564	in	abstract[130]	giv[130]	_	_
20-12	2565-2576	hepatocytes	abstract[130]|animal	giv[130]|giv	_	_
20-13	2577-2590	significantly	_	_	_	_
20-14	2591-2599	elevated	_	_	_	_
20-15	2600-2603	the	abstract[132]	giv[132]	_	_
20-16	2604-2614	expression	abstract[132]	giv[132]	_	_
20-17	2615-2617	of	abstract[132]	giv[132]	_	_
20-18	2618-2629	lipogenesis	abstract[132]|abstract|abstract[134]	giv[132]|new|giv[134]	_	_
20-19	2630-2637	factors	abstract[132]|abstract[134]	giv[132]|giv[134]	_	_
20-20	2638-2642	such	abstract[132]|abstract[134]	giv[132]|giv[134]	_	_
20-21	2643-2645	as	abstract[132]|abstract[134]	giv[132]|giv[134]	_	_
20-22	2646-2661	acetyl-coenzyme	abstract[132]|abstract[134]|substance[135]|substance[136]	giv[132]|giv[134]|new[135]|new[136]	_	_
20-23	2662-2663	A	abstract[132]|abstract[134]|substance[135]|substance[136]	giv[132]|giv[134]|new[135]|new[136]	_	_
20-24	2664-2675	carboxylase	abstract[132]|abstract[134]|substance[136]	giv[132]|giv[134]|new[136]	_	_
20-25	2676-2677	(	_	_	_	_
20-26	2678-2681	ACC	abstract	new	_	_
20-27	2682-2683	)	_	_	_	_
20-28	2684-2685	,	_	_	_	_
20-29	2686-2691	fatty	substance[138]|abstract[139]	giv[138]|new[139]	appos	20-33[0_139]
20-30	2692-2696	acid	substance[138]|abstract[139]	giv[138]|new[139]	_	_
20-31	2697-2705	synthase	abstract[139]	new[139]	_	_
20-32	2706-2707	(	_	_	_	_
20-33	2708-2711	FAS	abstract	giv	_	_
20-34	2712-2713	)	_	_	_	_
20-35	2714-2715	,	_	_	_	_
20-36	2716-2719	and	_	_	_	_
20-37	2720-2726	sterol	abstract|abstract[143]	new|new[143]	appos	20-42[0_143]
20-38	2727-2737	regulatory	abstract[142]|abstract[143]	new[142]|new[143]	_	_
20-39	2738-2753	element-binding	abstract[142]|abstract[143]	new[142]|new[143]	_	_
20-40	2754-2764	protein-1c	abstract[143]	new[143]	_	_
20-41	2765-2766	(	_	_	_	_
20-42	2767-2775	SREBP-1c	abstract	giv	_	_
20-43	2776-2777	)	_	_	_	_
20-44	2778-2779	.	_	_	_	_

#Text=Another study has shown that an HF diet destroyed the antioxidant defense system by decreasing superoxide dismutase ( SOD ) and catalase ( CAT ) activities , and markedly increased the production of ROS .
21-1	2780-2787	Another	abstract[145]	giv[145]	coref	26-4[186_145]
21-2	2788-2793	study	abstract[145]	giv[145]	_	_
21-3	2794-2797	has	_	_	_	_
21-4	2798-2803	shown	_	_	_	_
21-5	2804-2808	that	_	_	_	_
21-6	2809-2811	an	event[147]	giv[147]	_	_
21-7	2812-2814	HF	substance|event[147]	giv|giv[147]	_	_
21-8	2815-2819	diet	event[147]	giv[147]	_	_
21-9	2820-2829	destroyed	_	_	_	_
21-10	2830-2833	the	abstract[150]	new[150]	_	_
21-11	2834-2845	antioxidant	person|abstract[150]	new|new[150]	_	_
21-12	2846-2853	defense	abstract|abstract[150]	new|new[150]	_	_
21-13	2854-2860	system	abstract[150]	new[150]	_	_
21-14	2861-2863	by	_	_	_	_
21-15	2864-2874	decreasing	_	_	_	_
21-16	2875-2885	superoxide	substance|substance[152]|abstract[156]	new|new[152]|new[156]	appos	21-19[0_152]
21-17	2886-2895	dismutase	substance[152]|abstract[156]	new[152]|new[156]	_	_
21-18	2896-2897	(	abstract[156]	new[156]	_	_
21-19	2898-2901	SOD	substance|abstract[156]	giv|new[156]	_	_
21-20	2902-2903	)	abstract[156]	new[156]	_	_
21-21	2904-2907	and	abstract[156]	new[156]	_	_
21-22	2908-2916	catalase	object|abstract[156]	new|new[156]	appos	21-24
21-23	2917-2918	(	abstract[156]	new[156]	_	_
21-24	2919-2922	CAT	object|abstract[156]	giv|new[156]	_	_
21-25	2923-2924	)	abstract[156]	new[156]	_	_
21-26	2925-2935	activities	abstract[156]	new[156]	_	_
21-27	2936-2937	,	_	_	_	_
21-28	2938-2941	and	_	_	_	_
21-29	2942-2950	markedly	_	_	_	_
21-30	2951-2960	increased	_	_	_	_
21-31	2961-2964	the	abstract[157]	giv[157]	coref	22-16[163_157]
21-32	2965-2975	production	abstract[157]	giv[157]	_	_
21-33	2976-2978	of	abstract[157]	giv[157]	_	_
21-34	2979-2982	ROS	abstract[157]|substance	giv[157]|giv	coref	22-16
21-35	2983-2984	.	_	_	_	_

#Text=To prevent metabolic disorders due to oxidative stress , antioxidative capability that suppresses or eliminates ROS production plays an important role in the body .
22-1	2985-2987	To	_	_	_	_
22-2	2988-2995	prevent	_	_	_	_
22-3	2996-3005	metabolic	abstract[159]	giv[159]	_	_
22-4	3006-3015	disorders	abstract[159]	giv[159]	_	_
22-5	3016-3019	due	_	_	_	_
22-6	3020-3022	to	_	_	_	_
22-7	3023-3032	oxidative	abstract[160]	giv[160]	coref	27-11[200_160]
22-8	3033-3039	stress	abstract[160]	giv[160]	_	_
22-9	3040-3041	,	_	_	_	_
22-10	3042-3055	antioxidative	abstract[161]	new[161]	_	_
22-11	3056-3066	capability	abstract[161]	new[161]	_	_
22-12	3067-3071	that	abstract[161]	new[161]	_	_
22-13	3072-3082	suppresses	abstract[161]	new[161]	_	_
22-14	3083-3085	or	abstract[161]	new[161]	_	_
22-15	3086-3096	eliminates	abstract[161]	new[161]	_	_
22-16	3097-3100	ROS	abstract[161]|substance|abstract[163]	new[161]|giv|giv[163]	coref	23-14
22-17	3101-3111	production	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
22-18	3112-3117	plays	_	_	_	_
22-19	3118-3120	an	abstract[164]	new[164]	_	_
22-20	3121-3130	important	abstract[164]	new[164]	_	_
22-21	3131-3135	role	abstract[164]	new[164]	_	_
22-22	3136-3138	in	_	_	_	_
22-23	3139-3142	the	object[165]	giv[165]	coref	25-27[0_165]
22-24	3143-3147	body	object[165]	giv[165]	_	_
22-25	3148-3149	.	_	_	_	_

#Text=Plants contain a variety of phytochemicals that have antioxidant ability to effectively remove ROS .
23-1	3150-3156	Plants	plant	new	_	_
23-2	3157-3164	contain	_	_	_	_
23-3	3165-3166	a	abstract[167]	new[167]	_	_
23-4	3167-3174	variety	abstract[167]	new[167]	_	_
23-5	3175-3177	of	abstract[167]	new[167]	_	_
23-6	3178-3192	phytochemicals	abstract[167]|substance[168]	new[167]|new[168]	_	_
23-7	3193-3197	that	abstract[167]|substance[168]	new[167]|new[168]	_	_
23-8	3198-3202	have	abstract[167]|substance[168]	new[167]|new[168]	_	_
23-9	3203-3214	antioxidant	abstract[167]|substance[168]|abstract[169]	new[167]|new[168]|new[169]	_	_
23-10	3215-3222	ability	abstract[167]|substance[168]|abstract[169]	new[167]|new[168]|new[169]	_	_
23-11	3223-3225	to	abstract[167]|substance[168]|abstract[169]	new[167]|new[168]|new[169]	_	_
23-12	3226-3237	effectively	abstract[167]|substance[168]|abstract[169]	new[167]|new[168]|new[169]	_	_
23-13	3238-3244	remove	abstract[167]|substance[168]|abstract[169]	new[167]|new[168]|new[169]	_	_
23-14	3245-3248	ROS	abstract[167]|substance[168]|abstract[169]|substance	new[167]|new[168]|new[169]|giv	_	_
23-15	3249-3250	.	_	_	_	_

#Text=Curcuma longa L. is a flowering plant of the ginger family ( Zingiberaceae ) .
24-1	3251-3258	Curcuma	person[171]	new[171]	_	_
24-2	3259-3264	longa	person[171]	new[171]	_	_
24-3	3265-3267	L.	person[171]	new[171]	_	_
24-4	3268-3270	is	_	_	_	_
24-5	3271-3272	a	plant[172]	new[172]	_	_
24-6	3273-3282	flowering	plant[172]	new[172]	_	_
24-7	3283-3288	plant	plant[172]	new[172]	_	_
24-8	3289-3291	of	plant[172]	new[172]	_	_
24-9	3292-3295	the	plant[172]|person[173]	new[172]|new[173]	_	_
24-10	3296-3302	ginger	plant[172]|person[173]	new[172]|new[173]	_	_
24-11	3303-3309	family	plant[172]|person[173]	new[172]|new[173]	_	_
24-12	3310-3311	(	_	_	_	_
24-13	3312-3325	Zingiberaceae	place	new	_	_
24-14	3326-3327	)	_	_	_	_
24-15	3328-3329	.	_	_	_	_

#Text=As C. longa possesses natural antioxidants , which leads to free radical scavenging potential , it has been widely used to prevent many diseases , including liver injury .
25-1	3330-3332	As	_	_	_	_
25-2	3333-3335	C.	person|abstract[176]	new|new[176]	coref|coref	26-24|26-24[193_176]
25-3	3336-3341	longa	abstract[176]	new[176]	_	_
25-4	3342-3351	possesses	_	_	_	_
25-5	3352-3359	natural	substance[177]	giv[177]	_	_
25-6	3360-3372	antioxidants	substance[177]	giv[177]	_	_
25-7	3373-3374	,	substance[177]	giv[177]	_	_
25-8	3375-3380	which	substance[177]	giv[177]	_	_
25-9	3381-3386	leads	substance[177]	giv[177]	_	_
25-10	3387-3389	to	substance[177]	giv[177]	_	_
25-11	3390-3394	free	substance[177]|abstract[179]	giv[177]|new[179]	ana	25-16[0_179]
25-12	3395-3402	radical	substance[177]|abstract[179]	giv[177]|new[179]	_	_
25-13	3403-3413	scavenging	substance[177]|abstract|abstract[179]	giv[177]|new|new[179]	_	_
25-14	3414-3423	potential	substance[177]|abstract[179]	giv[177]|new[179]	_	_
25-15	3424-3425	,	_	_	_	_
25-16	3426-3428	it	abstract	giv	_	_
25-17	3429-3432	has	_	_	_	_
25-18	3433-3437	been	_	_	_	_
25-19	3438-3444	widely	_	_	_	_
25-20	3445-3449	used	_	_	_	_
25-21	3450-3452	to	_	_	_	_
25-22	3453-3460	prevent	_	_	_	_
25-23	3461-3465	many	abstract[181]	giv[181]	_	_
25-24	3466-3474	diseases	abstract[181]	giv[181]	_	_
25-25	3475-3476	,	abstract[181]	giv[181]	_	_
25-26	3477-3486	including	abstract[181]	giv[181]	_	_
25-27	3487-3492	liver	abstract[181]|object|event[183]	giv[181]|giv|new[183]	coref	26-30[195_0]
25-28	3493-3499	injury	abstract[181]|event[183]	giv[181]|new[183]	_	_
25-29	3500-3501	.	_	_	_	_

#Text=The aim of our study was to investigate in vitro and in vivo protective effects of hot water extract ( CLW ) from C. longa on the development of fatty liver .
26-1	3502-3505	The	abstract[184]	new[184]	_	_
26-2	3506-3509	aim	abstract[184]	new[184]	_	_
26-3	3510-3512	of	abstract[184]	new[184]	_	_
26-4	3513-3516	our	abstract[184]|person|abstract[186]	new[184]|acc|giv[186]	_	_
26-5	3517-3522	study	abstract[184]|abstract[186]	new[184]|giv[186]	_	_
26-6	3523-3526	was	_	_	_	_
26-7	3527-3529	to	_	_	_	_
26-8	3530-3541	investigate	_	_	_	_
26-9	3542-3544	in	abstract[187]|abstract[188]	new[187]|new[188]	_	_
26-10	3545-3550	vitro	abstract[187]|abstract[188]	new[187]|new[188]	_	_
26-11	3551-3554	and	abstract[188]	new[188]	_	_
26-12	3555-3557	in	abstract[188]	new[188]	_	_
26-13	3558-3562	vivo	abstract[188]	new[188]	_	_
26-14	3563-3573	protective	abstract[188]	new[188]	_	_
26-15	3574-3581	effects	abstract[188]	new[188]	_	_
26-16	3582-3584	of	abstract[188]	new[188]	_	_
26-17	3585-3588	hot	abstract[188]|substance[189]|substance[190]	new[188]|new[189]|new[190]	appos	26-21[0_190]
26-18	3589-3594	water	abstract[188]|substance[189]|substance[190]	new[188]|new[189]|new[190]	_	_
26-19	3595-3602	extract	abstract[188]|substance[190]	new[188]|new[190]	_	_
26-20	3603-3604	(	_	_	_	_
26-21	3605-3608	CLW	substance	giv	_	_
26-22	3609-3610	)	_	_	_	_
26-23	3611-3615	from	_	_	_	_
26-24	3616-3618	C.	person|abstract[193]	giv|giv[193]	_	_
26-25	3619-3624	longa	abstract[193]	giv[193]	_	_
26-26	3625-3627	on	_	_	_	_
26-27	3628-3631	the	event[194]	new[194]	_	_
26-28	3632-3643	development	event[194]	new[194]	_	_
26-29	3644-3646	of	event[194]	new[194]	_	_
26-30	3647-3652	fatty	event[194]|object[195]	new[194]|giv[195]	coref	27-15[0_195]
26-31	3653-3658	liver	event[194]|object[195]	new[194]|giv[195]	_	_
26-32	3659-3660	.	_	_	_	_

#Text=Furthermore , the mode of action against lipid accumulation and oxidative stress in non-alcoholic liver damage was determined .
27-1	3661-3672	Furthermore	_	_	_	_
27-2	3673-3674	,	_	_	_	_
27-3	3675-3678	the	abstract[196]	new[196]	_	_
27-4	3679-3683	mode	abstract[196]	new[196]	_	_
27-5	3684-3686	of	abstract[196]	new[196]	_	_
27-6	3687-3693	action	abstract[196]|event[197]	new[196]|new[197]	_	_
27-7	3694-3701	against	abstract[196]|event[197]	new[196]|new[197]	_	_
27-8	3702-3707	lipid	abstract[196]|event[197]|substance|abstract[199]	new[196]|new[197]|giv|giv[199]	_	_
27-9	3708-3720	accumulation	abstract[196]|event[197]|abstract[199]	new[196]|new[197]|giv[199]	_	_
27-10	3721-3724	and	abstract[196]|event[197]	new[196]|new[197]	_	_
27-11	3725-3734	oxidative	abstract[196]|event[197]|abstract[200]	new[196]|new[197]|giv[200]	_	_
27-12	3735-3741	stress	abstract[196]|event[197]|abstract[200]	new[196]|new[197]|giv[200]	_	_
27-13	3742-3744	in	abstract[196]|event[197]|abstract[200]	new[196]|new[197]|giv[200]	_	_
27-14	3745-3758	non-alcoholic	abstract[196]|event[197]|abstract[200]|event[202]	new[196]|new[197]|giv[200]|new[202]	_	_
27-15	3759-3764	liver	abstract[196]|event[197]|abstract[200]|object|event[202]	new[196]|new[197]|giv[200]|giv|new[202]	_	_
27-16	3765-3771	damage	abstract[196]|event[197]|abstract[200]|event[202]	new[196]|new[197]|giv[200]|new[202]	_	_
27-17	3772-3775	was	_	_	_	_
27-18	3776-3786	determined	_	_	_	_
27-19	3787-3788	.	_	_	_	_
